DK3290415T3 - Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme - Google Patents

Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme Download PDF

Info

Publication number
DK3290415T3
DK3290415T3 DK17173483.3T DK17173483T DK3290415T3 DK 3290415 T3 DK3290415 T3 DK 3290415T3 DK 17173483 T DK17173483 T DK 17173483T DK 3290415 T3 DK3290415 T3 DK 3290415T3
Authority
DK
Denmark
Prior art keywords
procedures
preparation
same
opioid receptor
receptor ligands
Prior art date
Application number
DK17173483.3T
Other languages
English (en)
Inventor
Dennis Yamashita
Dimitar Gotchev
Philip Pitis
Xiao-Tao Chen
Guodong Liu
Catherine C K Yuan
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46877853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3290415(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trevena Inc filed Critical Trevena Inc
Application granted granted Critical
Publication of DK3290415T3 publication Critical patent/DK3290415T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17173483.3T 2011-03-23 2012-03-23 Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme DK3290415T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466809P 2011-03-23 2011-03-23
US201261596808P 2012-02-09 2012-02-09
EP12760456.9A EP2688403B1 (en) 2011-03-23 2012-03-23 Opioid receptor ligands and methods of using and making same

Publications (1)

Publication Number Publication Date
DK3290415T3 true DK3290415T3 (da) 2021-03-22

Family

ID=46877853

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17173483.3T DK3290415T3 (da) 2011-03-23 2012-03-23 Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme
DK12760456.9T DK2688403T3 (da) 2011-03-23 2012-03-23 Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12760456.9T DK2688403T3 (da) 2011-03-23 2012-03-23 Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme

Country Status (22)

Country Link
US (8) US8835488B2 (da)
EP (3) EP3872076A1 (da)
JP (6) JP5912169B2 (da)
KR (3) KR101991326B1 (da)
CN (1) CN103702561B (da)
AU (2) AU2012230761B2 (da)
CA (1) CA2830742C (da)
CY (1) CY1119057T1 (da)
DK (2) DK3290415T3 (da)
EA (1) EA025456B1 (da)
ES (2) ES2632009T3 (da)
HK (1) HK1250984A1 (da)
HR (1) HRP20171021T1 (da)
HU (2) HUE054055T2 (da)
IL (4) IL228506A (da)
LT (1) LT2688403T (da)
ME (1) ME02754B (da)
PL (2) PL2688403T3 (da)
PT (2) PT3290415T (da)
RS (1) RS56111B1 (da)
SI (1) SI2688403T1 (da)
WO (1) WO2012129495A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101991326B1 (ko) 2011-03-23 2019-06-20 트레베나, 인코포레이티드. 오피오이드 수용체 리간드와 그 용도 및 제조방법
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2017049177A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
SG10202110242YA (en) 2015-09-16 2021-10-28 Metacrine Inc Farnesoid x receptor agonists and uses thereof
US10626081B2 (en) 2015-09-16 2020-04-21 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
EP3354649B1 (en) * 2015-10-15 2019-12-04 Jiangsu Hengrui Medicine Co., Ltd. Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
CN106588899B (zh) * 2015-10-15 2019-11-15 江苏恒瑞医药股份有限公司 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
JP6991993B2 (ja) 2015-12-14 2022-01-13 トレベナ・インコーポレイテッド 痛覚過敏を治療する方法
WO2017105881A1 (en) * 2015-12-15 2017-06-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain
AU2016370860A1 (en) * 2015-12-17 2018-07-12 Trevena, Inc. Combinations of opioid receptor ligands and cytochrome P450 inhibitors
CN107098876B (zh) * 2016-02-23 2021-04-06 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
US20200330444A1 (en) * 2016-07-01 2020-10-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain and related diseases and conditions, and compositions and methods thereof
PT3597646T (pt) 2016-08-19 2023-09-11 Gilead Sciences Inc Compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infeção pelo vírus hiv
EP3555072A1 (en) * 2016-12-16 2019-10-23 Esteve Pharmaceuticals, S.A. Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain
JP7185633B2 (ja) * 2017-02-17 2022-12-07 トレベナ・インコーポレイテッド ７員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法
JP7316216B2 (ja) 2017-02-17 2023-07-27 トレベナ・インコーポレイテッド ５員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法
KR102588982B1 (ko) 2017-03-15 2023-10-12 오가노보, 인크. 파네소이드 x 수용체 효능제 및 이의 용도
US10961198B2 (en) 2017-03-15 2021-03-30 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
US20200054594A1 (en) * 2017-04-14 2020-02-20 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
JP7153030B6 (ja) 2017-04-14 2023-07-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法
CN108727347B (zh) * 2017-04-14 2020-06-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
CN115124520A (zh) * 2017-07-04 2022-09-30 四川海思科制药有限公司 阿片受体激动剂及其应用
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
US11072601B2 (en) 2017-09-18 2021-07-27 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine
AU2018341782A1 (en) 2017-09-28 2020-04-16 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing oxaspirocycle derivative, and intermediate thereof
US11124523B2 (en) 2017-10-13 2021-09-21 Shandong Luye Pharmaceutical Co., Ltd. 2,6-dioxaspiro [4,5] decane derivatives and preparation method therefor and pharmaceutical applications thereof
WO2019109937A1 (zh) 2017-12-06 2019-06-13 江苏恒瑞医药股份有限公司 Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途
EP3749667A1 (en) 2018-02-05 2020-12-16 Alkermes, Inc. Compounds for the treatment of pain
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
CN111163778B (zh) * 2018-05-14 2023-01-24 江苏恒瑞医药股份有限公司 一种mor受体激动剂药物组合物
TWI814350B (zh) 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US11084817B2 (en) 2018-09-18 2021-08-10 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2020073984A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112638907B (zh) * 2018-10-12 2022-04-12 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112334465A (zh) * 2019-01-17 2021-02-05 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
AU2020391466A1 (en) 2019-11-26 2022-07-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
US20230147833A1 (en) 2020-01-17 2023-05-11 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Optically pure oxaspiro-substituted pyrrolopyrazole derivative, preparation method therefor and pharmaceutical use thereof
CN113412263A (zh) 2020-01-17 2021-09-17 上海海雁医药科技有限公司 氮杂双环取代的氧杂螺环衍生物、其制法与医药上的用途
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
CN115996925A (zh) 2020-06-25 2023-04-21 吉利德科学公司 用于治疗hiv的衣壳抑制剂
CN114269738B (zh) * 2020-08-10 2023-09-29 成都苑东生物制药股份有限公司 一种mor受体激动剂化合物、制备方法及其用途
CN112694485B (zh) * 2020-09-10 2023-04-07 四川海品信医药科技有限公司 一种阿片受体激动剂噻吩类化合物及其制备方法
CN116368138A (zh) 2020-12-29 2023-06-30 上海海雁医药科技有限公司 氧杂螺环取代的吡咯并吡唑衍生物及其中间体和制备方法
CA3225477A1 (en) 2021-07-13 2023-01-19 Shanghai Haiyan Pharmaceutical Technology Co. Ltd Pharmaceutically acceptable salt of mor receptor agonist, and polymorph thereof and use thereof
WO2023011422A1 (zh) * 2021-08-02 2023-02-09 上海枢境生物科技有限公司 氧杂螺环类衍生物、制备方法及其用途
WO2023030319A1 (zh) * 2021-08-31 2023-03-09 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN116041336A (zh) * 2022-01-21 2023-05-02 成都苑东生物制药股份有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN116589451A (zh) * 2022-02-11 2023-08-15 成都苑东生物制药股份有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
US5223530A (en) 1990-07-31 1993-06-29 Sri, International Arylcycloalkanepolyalkylamine ligands
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
AU3192295A (en) * 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
EP0833622B8 (en) 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
CN1305852C (zh) * 2002-09-19 2007-03-21 伊莱利利公司 作为阿片受体拮抗剂的二芳基醚
KR20140015122A (ko) * 2003-10-01 2014-02-06 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
US20100022637A1 (en) * 2005-09-29 2010-01-28 The Trustees Of Columbia University In The City Of New York Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof
US20070203224A1 (en) * 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US8067447B2 (en) * 2006-11-01 2011-11-29 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2008057857A1 (en) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
WO2009018169A1 (en) 2007-07-27 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
PT2260042E (pt) * 2008-03-27 2011-12-06 Gruenenthal Gmbh Derivados de ciclo-hexano espirocíclicos substituídos
FR2939136B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
FR2967672B1 (fr) * 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
KR101991326B1 (ko) * 2011-03-23 2019-06-20 트레베나, 인코포레이티드. 오피오이드 수용체 리간드와 그 용도 및 제조방법
JP6991993B2 (ja) 2015-12-14 2022-01-13 トレベナ・インコーポレイテッド 痛覚過敏を治療する方法

Also Published As

Publication number Publication date
IL284407B2 (en) 2023-04-01
IL272165A (en) 2020-03-31
US20120245181A1 (en) 2012-09-27
CY1119057T1 (el) 2018-01-10
US20190343819A1 (en) 2019-11-14
CA2830742A1 (en) 2012-09-27
US11077098B2 (en) 2021-08-03
PT3290415T (pt) 2021-03-29
PL2688403T3 (pl) 2017-09-29
KR102129247B1 (ko) 2020-07-06
PT2688403T (pt) 2017-07-13
IL284407B (en) 2022-12-01
JP2014508811A (ja) 2014-04-10
HK1250984A1 (zh) 2019-01-18
CA2830742C (en) 2023-03-14
IL243318A0 (en) 2016-02-29
KR101991327B1 (ko) 2019-06-20
CN103702561A (zh) 2014-04-02
DK2688403T3 (da) 2017-07-24
PL3290415T3 (pl) 2021-07-19
US20150246904A1 (en) 2015-09-03
EA201391332A1 (ru) 2014-04-30
NZ615993A (en) 2015-11-27
JP2023075282A (ja) 2023-05-30
US10588898B2 (en) 2020-03-17
US11931350B2 (en) 2024-03-19
EP3290415B1 (en) 2020-12-30
KR101991326B1 (ko) 2019-06-20
HRP20171021T1 (hr) 2017-09-22
EP2688403B1 (en) 2017-05-31
IL243318B (en) 2020-02-27
SI2688403T1 (sl) 2017-08-31
JP2018048193A (ja) 2018-03-29
US9309234B2 (en) 2016-04-12
HUE032948T2 (en) 2017-11-28
AU2012230761B2 (en) 2016-11-03
JP2016155843A (ja) 2016-09-01
EP3290415A1 (en) 2018-03-07
ES2857549T3 (es) 2021-09-29
US9642842B2 (en) 2017-05-09
JP5912169B2 (ja) 2016-04-27
US9849119B2 (en) 2017-12-26
CN103702561B (zh) 2017-02-22
ME02754B (me) 2018-01-20
US9044469B2 (en) 2015-06-02
EP3872076A1 (en) 2021-09-01
EA025456B1 (ru) 2016-12-30
JP2021176885A (ja) 2021-11-11
IL272165B (en) 2021-07-29
NZ713143A (en) 2017-05-26
AU2017200745A1 (en) 2017-02-23
JP6243949B2 (ja) 2017-12-06
US20180311222A1 (en) 2018-11-01
KR20190072665A (ko) 2019-06-25
WO2012129495A1 (en) 2012-09-27
US8835488B2 (en) 2014-09-16
KR20180100453A (ko) 2018-09-10
US20160250199A1 (en) 2016-09-01
US20170326124A1 (en) 2017-11-16
JP2020073570A (ja) 2020-05-14
AU2012230761A1 (en) 2013-05-02
AU2017200745B2 (en) 2018-02-22
US20220175747A1 (en) 2022-06-09
HUE054055T2 (hu) 2021-08-30
BR112013024136A2 (pt) 2020-01-14
EP2688403A4 (en) 2014-10-15
RS56111B1 (sr) 2017-10-31
IL284407A (en) 2021-08-31
IL228506A0 (en) 2013-12-31
EP2688403A1 (en) 2014-01-29
JP6649341B2 (ja) 2020-02-19
JP7248750B2 (ja) 2023-03-29
KR20140047599A (ko) 2014-04-22
LT2688403T (lt) 2017-07-25
US20130331408A1 (en) 2013-12-12
JP6923683B2 (ja) 2021-08-25
ES2632009T3 (es) 2017-09-07
IL228506A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
DK3290415T3 (da) Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
CO7020859A2 (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2919923T3 (da) Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK2768796T3 (da) Fremgangsmåde til fremstilling af quinolin-derivater
DK2704703T3 (da) Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
DK2616035T3 (da) Indretning til at hjælpe med at gå med støtte
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK2920151T3 (da) Fremgangsmåde til fremstilling af carboxamider
DK2871184T3 (da) Benzodioxolderivat og fremgangsmåde til fremstilling og anvendelse deraf
DK2558473T3 (da) Fremgangsmåde til fremstilling af dithiin-tetracarboximider
DK3517532T3 (da) Fremgangsmåde til fremstilling af anamorelinhydrochlorid med reguleret chloridindhold
DK2655360T3 (da) Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler
DK2745928T3 (da) Fremgangsmåde til emulsionsfremstilling
DK2694049T3 (da) Tapentadol til forebyggelse af kronificering af smerte
PL395070A1 (pl) Herbata odchudzajaca
EP2747562A4 (en) ESTROGEN RECEPTOR LIGANDS AND METHODS OF USING SAME